ReviewAAPS PharmSciTech2026
Stimuli-Responsive Hydrogel Systems for Breast Cancer Therapy: Advances in Targeted Delivery and Tumor Microenvironment Modulation.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) stands as a major medical concern for women because treatment hurdles include drug resistance combined with treatment failure and severe side effects and the intricate tumor microenvironment (TME). The treatment-resistant breast cancer subtype triple-negative breast cancer (TNBC) exhibits high aggressiveness through its failure to respond to targeted treatment yet maintains substantial metastatic potential. Hydrogels that react to stimuli have recently shown promise as solutions for solving these clinical issues. These hydrogels show response to precise stimuli which include pH, temperature and light and magnetic fields and biological elements including glutathione together with overexpressed enzymes MMP2 and MMP9 that appear within BC tumors. Hydrogel systems that respond to enzymes release drugs precisely at tumors thus minimizing drug side effects and optimizing their therapeutic effects. Hydrogel systems become more effective because of their ability to control drug delivery and combine various treatments when nanomaterials are incorporated as parts of their structure. Hydrogels must have adequate mechanical toughness because it enables them to withstand physical pressure without losing their drug release capabilities throughout the extended treatment period. This review has demonstrated that hydrogel-based drug delivery systems decrease tumor dimensions while inhibiting metastasis making them an advanced treatment strategy for BC management. The novel hydrogel platforms will lead to individualized treatment methods which show substantial promise to enhance breast cancer therapy results.
Indexed as
Identifiers
42844427What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.